Claims
- 1. A cyclic ketone compound represented by formula (I): where R1, R2 and R3 are independently a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, C1 to C10 alkenyl group, C1 to C10 alkynyl group, C6 to C12 aryl group, C6 to C12 arylalkyl group, C6 to C12 alkylaryl group, C6 to C12 arylalkenyl group, or —(CH2)pZ (where p represents an integer in the range 0 to 3, and Z represents a cyano group, carboxyl group, methylthio group, phenylthio group, trifluoromethyl group or methylthiomethyl group, with the proviso that R1, R2 and R3 are not all substituents selected from the hydrogen atom, fluorine atom, chlorine atom and bromine atom, R4 and R5 respectively independently represent a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C6 alkyl group, hydroxy group, C1 to C6 alkoxy group, carboxy group or C2 to C10 alkoxycarbonyl group, R6 represents a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, C6 to C12 aryl group, C6 to C12 arylalkyl group, C6 to C12 alkylaryl group, C6 to C12 arylalkenyl group, or —(CH2)qG (where q represents an integer in the range 1 to 3, and G represents a hydroxyl group or C2 to C10 alkoxycarbonyl group), R7 represents a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, C6 to C12 aryl group, carboxy group or C2 to C10 alkoxycarbonyl group, R8 represents a hydrogen atom or C1 to C10 alkyl group, X is O or S, and Y is O or S, or pharmacologically acceptable salts thereof.
- 2. The cyclic ketone compound or pharmacologically acceptable salt thereof according to claim 1, where R1 to R5 are independently a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, or substituted or unsubstituted phenyl group, and R6 and R7 are independently a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, or substituted or unsubstituted phenyl group.
- 3. The cyclic ketone compound of pharmacologically acceptable salt thereof according to claim 1, where R6 represents a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, C6 to C12 aryl group, C6 to C12 arylalkyl group, C6 to C12 alkylaryl group, C6 to C12 arylalkenyl group, or —(CH2)qG (where q represents an integer in the range 1 to 3, and G represents a hydroxyl group or C2 to C10 alkoxycarbonyl group), and R7 represents a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, C6 to C12 aryl group, carboxy group or C2 to C10 alkoxycarbonyl group.
- 4. The cyclic ketone compound or pharmacologically acceptable salt thereof according to claim 1, where R1 to R3 are independently a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, or substituted or unsubstituted phenyl group, R4 is a hydrogen atom, R5 is a hydrogen atom, R6 is a hydrogen atom, C1 to C10 alkyl group, or substituted or unsubstituted phenyl group, R7 is a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, or substituted or unsubstituted phenyl group, or and R8 is a hydrogen atom.
- 5. A pharmaceutical composition comprising the cyclic ketone compound of claim 1 or pharmacologically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
- 6. A method for the treating or preventing cytopaenia comprising administering to a subject in need of same an effective amount of the compound of claim 1 or pharmacologically acceptable salt thereof.
- 7. A method for increasing blood cells comprising administering to a subject in need of same an effective amount of a cyclic ketone compound of claim 1 or pharmacologically acceptable salt thereof.
- 8. A process for preparing a cyclic ketone compound according to claim 1 comprising condensing a ketone represented by formula (II) and a carboxylic acid or carboxylic acid derivative represented by formula (III) where R1, R2 and R3 are independently a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, C1 to C10 alkenyl group, C1 to C10 alkynyl group, C6 to C12 aryl group, C6 to C12 arylalkyl group, C6 to C12 alkylaryl group, C6 to C12 arylalkenyl group, —(CH2)pZ (where p represents an integer in the range 0 to 3, and Z represents a cyano group, carboxyl group, methylthio group, phenylthio group, trifluoromethyl group or methylthiomethyl group with the proviso that R1, R2 and R3 are all not substituents selected from hydrogen atom, fluorine atom, chlorine atom and bromine atom, R4 and R5 respectively independently represent a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C6 alkyl group, hydroxyl group, C1 to C6 alkoxy group, carboxy group or C2 to C10 alkoxycarbonyl group, R6 represents a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, C6 to C12 aryl group, C6 to C12 arylalkyl group, C6 to C12 alkylaryl group, C6 to C12 arylalkenyl group, —(CH2)qG (where q represents an integer in the range 1 to 3, and G represents a hydroxyl group or C2 to C10 alkoxycarbonyl group), R7 represents a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, C6 to C12 aryl group, carboxy group or C2 to C10 alkoxycarbonyl group, R8 represents a hydrogen atom or a C1 to C10 alkyl group, X represents O or S, Y represents O or S, and R9 is a C1 to C10 alkyl group or a phenyl group.
- 9. The process of claim 8, where R6 represents a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, C6 to C12 aryl group, C6 to C12 arylalkyl group, C6 to C12 alkylaryl group, C6 to C12 arylalkenyl group, or —(CH2)qG (where q represents an integer in the range 1 to 3, and G represents a hydroxyl group or C2 to C10 alkoxycarbonyl group), and R7 represents a hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1 to C10 alkyl group, C6 to C12 aryl group, carboxy group or C2 to C10 alkoxycarbonyl group.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9-262033 |
Sep 1997 |
JP |
|
Parent Case Info
This application is a continuation of PCT/JP98/04317 filed Sep. 25, 1998 and also claims priority of Japanese patent application 262033/97 filed Sep. 26, 1997.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3489774 |
Kuhn et al. |
Jan 1970 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
0 841 063 A1 |
May 1998 |
EP |
5046666 |
Apr 1975 |
JP |
9735565 |
Oct 1997 |
WO |
Non-Patent Literature Citations (2)
Entry |
STN search report, Registry no's in WO 9735565 and JP 50046666 and US3489774, Aug. 30, 1999. |
Rowley et al J. Med. Chem. 1993, 36, 3386-3396 3-Acyl-4-hydroxyquinolin-2 (1H)-ones. Systemically etc. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/JP98/04317 |
Sep 1998 |
US |
Child |
09/317925 |
|
US |